Page 183 of 291 · 8,722 total

patent instituted · Sep 2, 2024

Juniper Networks, Inc v.Monarch Networking Solutions LLC

· IPR2024-00565

Juniper Networks successfully petitioned to challenge Monarch Networking Solutions' patent on grounds of obviousness (35 U.S.C. § 103). The Board found a reasonable likelihood of success, leading to the institution of the IPR proceedings against claims 1 and 5-8.

patent denied · Sep 2, 2024

DISH Network L.L.C. et al. v.Entropic Communications LLC

· IPR2024-00562

DISH Network L.L.C.'s attempt to invalidate 40 claims of Entropic Communications' patent (8363681) was denied by the PTAB. The Board found insufficient evidence that the claimed clock synchronization methods were obvious over prior art, including IEEE802.3ah and Shvodian.

patent denied · Sep 2, 2024

DISH Network L.L.C. et al. v.Entropic Communications LLC

· IPR2024-00560

The PTAB denied institution of IPR for DISH Network against Entropic Communications, finding that the challenger failed to establish a reasonable likelihood of prevailing on grounds of obviousness. The challenge related to common bit-loading methods in broadband coaxial networks.

patent instituted · Sep 2, 2024

Samsung Electronics Co., Ltd. et al. v.Staton Techiya LLC

· IPR2024-00559

The PTAB granted institution of IPR for Samsung against Staton Techiya regarding U.S. Patent 11,610,587, focusing on audio management and sonic signature detection.

patent instituted · Sep 2, 2024

Microsoft Corporation et al. v.InterDigital Patent Holdings, Inc. et al.

· IPR2024-00538

Microsoft Corporation successfully challenged InterDigital Patent Holdings, Inc.'s patent claims in a PTAB decision. The Board found that the petitioner demonstrated a reasonable likelihood of prevailing on all asserted grounds regarding anticipation and obviousness. This institution decision keeps the dispute alive for further review.

patent instituted · Sep 2, 2024

Microsoft Corporation et al. v.InterDigital Patent Holdings, Inc. et al.

· IPR2024-00537

The PTAB instituted an IPR challenge against InterDigital's patent 8737933, finding a reasonable likelihood of prevailing for Microsoft. The Board rejected the Patent Owner's attempt to secure discretionary denial, moving the case to the merits phase.

patent instituted · Sep 2, 2024

Dexcom, Inc. v.Abbott Diabetes Care Inc.

· IPR2024-00521

Dexcom successfully petitioned to institute an IPR against Abbott Diabetes Care Inc.'s glucose monitoring patent (11298056). The Board found a reasonable likelihood of prevailing on grounds of obviousness (103) for claims 13 and 29.

patent final · Sep 2, 2024

Microsoft Corporation et al. v.InterDigital Patent Holdings, Inc. et al.

· IPR2024-00538

The Board upheld the validity of patent 9173054 after finding that the priority date (December 22, 2009) disqualified all cited prior art under Sections 102 and 103. The Patent Owner successfully argued that the ancestor application sufficiently described both Bluetooth detection and Wi-Fi data transfer methods.

patent final · Sep 2, 2024

Microsoft Corporation et al. v.InterDigital Patent Holdings, Inc. et al.

· IPR2024-00537

The Board issued a final written decision finding that the challenged claims were not unpatentable. The Board upheld the patent owner's position regarding priority and found that the specification adequately supported the combination of Bluetooth detection and Wi-Fi data transfer.

patent · Sep 1, 2024

TransCore LP v.Hand Held Products, Inc.

· IPR2024-00391

Hand Held Products argues that TransCore's IPR petition fails because the cited Katz reference is not a printed publication and the petitioner’s reliance on Tolonen and Ishizu lacks the required particularity. The owner seeks denial of institution and invokes §325(d).

patent terminated or settled · Sep 1, 2024

TransCore LP v.Hand Held Products, Inc.

· IPR2024-00391

TransCore and Hand Held Products entered a settlement that resolved all disputes over three patents. The parties jointly moved to terminate the IPRs, and the Board granted the termination and kept the settlement confidential.

patent terminated or settled · Sep 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00383

EndyMed Medical and Serendia settled their inter partes review disputes over U.S. Patent 9,775,774, leading the PTAB to terminate the proceedings and keep the settlement confidential.

patent · Sep 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00383

Serendia requests the USPTO Director to vacate the institution of an IPR against its dermatology device patent after the ITC upheld the patent’s validity, arguing the Board abused discretion and that the Fintiv factors favor denial.

patent · Sep 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00383

EndyMed Medical and Serendia have settled their IPR dispute over U.S. Patent 9,775,774. The parties jointly filed a motion requesting the Board terminate the proceeding before any oral hearing.

patent terminated or settled · Sep 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00383

The PTAB granted a settlement‑based termination for Jeisys Medical in three IPRs while allowing the proceedings to continue for EndyMed. The settlement agreement was ordered to be kept confidential.

patent · Sep 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00383

Jeisys Medical and Serendia have filed a joint request in IPR2024-00383 to keep their settlement agreement confidential under 35 U.S.C. § 317(b). The parties seek to have the agreement treated as business confidential information and kept separate from the patent file.

patent · Sep 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00383

During an IPR hearing, Jeisys Medical announced a settlement with SHEnB and Cartessa respondents, seeking to suspend the schedule until November 20.

patent terminated or settled · Sep 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00383

Jeisys Medical and Serendia settled their IPR dispute over U.S. Patent 9,775,774 and jointly moved to terminate the proceeding.

patent · Sep 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00383

Court decision.

patent terminated or settled · Sep 1, 2024

TransCore LP v.Hand Held Products, Inc.

· IPR2024-00391

TransCore and Hand Held Products entered a confidential settlement and jointly moved to terminate IPR2024-00391 concerning U.S. Patent 8,141,784. The Board has not yet decided the merits, and the parties request termination to conserve resources.

patent · Sep 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00383

EndyMed Medical and Serendia have filed a joint request to keep their settlement agreement confidential under statutory provisions, separating it from the patent record.

patent null · Sep 1, 2024

TransCore LP v.Hand Held Products, Inc.

· IPR2024-00391

TransCore LP challenges U.S. Patent No. 8,141,784 in the PTAB, asserting that the claims are unpatentable over prior art references Tolonen and Katz. The petitioner argues that the core features of the patent—such as EIR terminals connecting chipsets to baseband software—are anticipated or obvious based on these older technologies.

patent null · Sep 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00383

Jeisys Medical Inc. challenged Serendia, LLC's '774 patent in an IPR petition, asserting that claims are anticipated by Mehta and rendered obvious through combinations involving Na ’848 and Lee. The petition focuses on the unpatentability of medical device claims related to dermatological treatment/microneedling.

patent instituted · Sep 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00383

The PTAB instituted an IPR challenging claims 13 and 14 of Serendia's patent, finding a reasonable likelihood of anticipation by the prior art reference Mehta. The case moves to trial phase after rejecting arguments for discretionary denial based on competitor relationships.

patent some challenged claims unpatentable · Aug 30, 2024

Simpson Strong-Tie Company Inc. et al. v.Columbia Insurance Company et al.

· PGR2024-00050

The PTAB issued a Final Written Decision in PGR2024‑00050, finding claims 5 and 17 indefinite and lacking written description, and deeming claims 1‑12, 15‑17, and 21‑23 obvious over Gilb ’792 and Bundy. The Board granted a partial amendment for claim 32 while denying other proposed substitute claims.

patent mixed - some claims cancelled, some upheld · Aug 30, 2024

Simpson Strong-Tie Company Inc. et al. v.Columbia Insurance Company et al.

· PGR2024-00050

The PTAB found 103 of the 105 claims of Simpson Strong‑Tie’s fire‑wall hanger patent unpatentable as obvious over a combination of Yamaguchi, Bundy, Adams and Gilb ’416 references. Claims 38 and 91 were left intact. The Board adopted petitioner‑proposed claim constructions.

patent · Aug 30, 2024

Simpson Strong-Tie Company Inc. et al. v.Columbia Insurance Company et al.

· PGR2024-00050

Simpson Strong‑Tie challenges Columbia Insurance’s post‑grant review of U.S. Patent 11,920,339 covering fire‑wall hanger systems. The patent owner’s sur‑reply argues the petition’s obviousness and written‑description attacks fail, emphasizing strong secondary‑consideration evidence. The case remains pending before the PTAB.

patent · Aug 30, 2024

Simpson Strong-Tie Company Inc. et al. v.Columbia Insurance Company et al.

· PGR2024-00050

Simpson Strong‑Tie and Columbia Insurance have settled their dispute over U.S. Patent 11,920,339 and jointly filed a request to keep the settlement agreement confidential while moving to terminate the post‑grant review.

patent terminated or settled · Aug 30, 2024

Simpson Strong-Tie Company Inc. et al. v.Columbia Insurance Company et al.

· PGR2024-00050

Simpson Strong‑Tie and Columbia Insurance have settled their dispute over U.S. Patent 11,920,339 and jointly moved to terminate the post‑grant review. The Board is asked to dismiss the proceeding under its authority to end settled cases.

patent terminated or settled · Aug 30, 2024

Simpson Strong-Tie Company Inc. et al. v.Columbia Insurance Company et al.

· PGR2024-00050

Simpson Strong‑Tie and Columbia Insurance reached a confidential settlement, prompting the PTAB to terminate the post‑grant review of patent 11,920,339. The Board granted the joint motion to keep the settlement confidential and end the proceeding.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →